In a recent seminar by GCDTR’s Dr. Scott Isaacs, MD, FACP, FACE, shared a comprehensive overview of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD, formerly NAFLD). He discussed the global burden of the disease, the updated diagnostic terminology, and practical tools for risk stratification, including FIB-4, VCTE (FibroScan), ELF, and MRE.
Dr. Isaacs also highlighted effective treatment strategies such as achieving ≥10% weight loss and using emerging therapies like GLP-1/GIP receptor agonists, SGLT2 inhibitors, pioglitazone, and resmetirom. The session emphasized early detection of liver fibrosis and improving outcomes for individuals with diabetes and obesity.
Watch the full recording: lnkd.in/gzZaxZz6
